Your browser doesn't support javascript.
Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19.
Schindler, Suzanne E; Jicha, Gregory A; Nelson, Peter T; Keene, C Dirk; Blennow, Kaj; Molinuevo, José Luis; Masters, Colin L; Hansson, Oskar; Teunissen, Charlotte E; Galasko, Douglas; Shaw, Leslie M; Levey, Allan I; Silverberg, Nina.
  • Schindler SE; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
  • Jicha GA; Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.
  • Nelson PT; Department of Neurology, University of Kentucky, Lexington, KY, USA.
  • Keene CD; Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA.
  • Blennow K; Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA.
  • Molinuevo JL; Department of Pathology, University of Kentucky, Lexington, KY, USA.
  • Masters CL; Department of Pathology, University of Washington, Seattle, WA, USA.
  • Hansson O; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University Gothenburg, Mölndal, Sweden.
  • Teunissen CE; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Galasko D; Barcelonaßeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain.
  • Shaw LM; Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clinic, Barcelona, Spain.
  • Levey AI; The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia.
  • Silverberg N; Department of Clinical Sciences, Clinical Memory Research Unit, Lund University, Lund, Sweden.
J Alzheimers Dis ; 76(1): 27-31, 2020.
Article in English | MEDLINE | ID: covidwho-637281
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic led to an abrupt halt of many Alzheimer's disease (AD) research studies at sites spanning the world. This is especially true for studies requiring in-person contact, such as studies collecting biofluids. Since COVID-19 is likely to remain a threat for an extended period, the resumption of fluid biomarker studies requires the development and implementation of procedures that minimize the risk of in-person visits to participants, staff, and individuals handling the biofluid samples. Some issues to consider include structuring the visit workflow to minimize contacts and promote social distancing; screening and/or testing participants and staff for COVID-19; wearing masks and performing hand hygiene; and precautions for handling, storing, and analyzing biofluids. AD fluid biomarker research remains a vitally important public health priority and resuming studies requires appropriate safety procedures to protect research participants and staff.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Health Personnel / Coronavirus Infections / Alzheimer Disease / Patient Safety / Personal Protective Equipment / Betacoronavirus Type of study: Diagnostic study Limits: Humans Language: English Journal: J Alzheimers Dis Journal subject: Geriatrics / Neurology Year: 2020 Document Type: Article Affiliation country: JAD-200684

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Health Personnel / Coronavirus Infections / Alzheimer Disease / Patient Safety / Personal Protective Equipment / Betacoronavirus Type of study: Diagnostic study Limits: Humans Language: English Journal: J Alzheimers Dis Journal subject: Geriatrics / Neurology Year: 2020 Document Type: Article Affiliation country: JAD-200684